These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 25942475

  • 1. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.
    Lee WS, Pyun BJ, Kim SW, Shim SR, Nam JR, Yoo JY, Jin Y, Jin J, Kwon YG, Yun CO, Nam DH, Oh K, Lee DS, Lee SH, Yoo JS.
    MAbs; 2015; 7(5):957-68. PubMed ID: 25942475
    [Abstract] [Full Text] [Related]

  • 2. Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis.
    Kim DG, Jin Y, Jin J, Yang H, Joo KM, Lee WS, Shim SR, Kim SW, Yoo J, Lee SH, Yoo JS, Nam DH.
    MAbs; 2015; 7(6):1195-204. PubMed ID: 26325365
    [Abstract] [Full Text] [Related]

  • 3. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X, Yue GG, Liu M, Zuo Z, Lee JK, Li M, Tsui SK, Fung KP, Sun H, Pu J, Lau CB.
    Oncotarget; 2016 Dec 13; 7(50):82820-82835. PubMed ID: 27756875
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model.
    Kim J, Choi SH, Ham SJ, Cho YC, Lee SI, Kang J, Woo DC, Lee WS, Yoo JS, Kim KW, Choi Y.
    PLoS One; 2018 Dec 13; 13(1):e0187063. PubMed ID: 29370209
    [Abstract] [Full Text] [Related]

  • 5. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW, Lien JC, Kuo SC, Huang TF.
    Carcinogenesis; 2012 May 13; 33(5):1022-30. PubMed ID: 22436611
    [Abstract] [Full Text] [Related]

  • 6. Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2.
    Erdag B, Balcioglu BK, Bahadir AO, Serhatli M, Kacar O, Bahar A, Seker UO, Akgun E, Ozkan A, Kilic T, Tamerler C, Baysal K.
    Biotechnol Appl Biochem; 2011 May 13; 58(6):412-22. PubMed ID: 22172104
    [Abstract] [Full Text] [Related]

  • 7. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
    Lien JC, Chung CL, Huang TF, Chang TC, Chen KC, Gao GY, Hsu MJ, Huang SW.
    Br J Pharmacol; 2019 Oct 13; 176(20):4034-4049. PubMed ID: 31368127
    [Abstract] [Full Text] [Related]

  • 8. 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway.
    Xu HY, Pan YM, Chen ZW, Lin Y, Wang LH, Chen YH, Jie TT, Lu YY, Liu JC.
    J Ethnopharmacol; 2013 Apr 19; 146(3):724-33. PubMed ID: 23434607
    [Abstract] [Full Text] [Related]

  • 9. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.
    Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z.
    Int J Cancer; 2002 Jan 20; 97(3):393-9. PubMed ID: 11774295
    [Abstract] [Full Text] [Related]

  • 10. Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway.
    Tang N, Shi L, Yu Z, Dong P, Wang C, Huo X, Zhang B, Huang S, Deng S, Liu K, Ma T, Wang X, Wu L, Ma XC.
    Oncotarget; 2016 Jan 19; 7(3):3533-47. PubMed ID: 26657289
    [Abstract] [Full Text] [Related]

  • 11. Xiaotan Sanjie decoction inhibits angiogenesis in gastric cancer through Interleukin-8-linked regulation of the vascular endothelial growth factor pathway.
    Shi J, Lu Y, Wei P.
    J Ethnopharmacol; 2016 Aug 02; 189():230-7. PubMed ID: 27224240
    [Abstract] [Full Text] [Related]

  • 12. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
    Hosseini H, Rajabibazl M, Ebrahimizadeh W, Dehbidi GR.
    Microvasc Res; 2015 Jan 02; 97():13-8. PubMed ID: 25250517
    [Abstract] [Full Text] [Related]

  • 13. The antiangiogenic activity of a soluble fragment of the VEGFR extracellular domain.
    Li H, Cao W, Chen Z, Acheampong DO, Jin H, Li D, Zhang J, Wang M.
    Biomed Pharmacother; 2013 Sep 02; 67(7):599-606. PubMed ID: 23906761
    [Abstract] [Full Text] [Related]

  • 14. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.
    Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z.
    J Biol Chem; 2003 Oct 31; 278(44):43496-507. PubMed ID: 12917408
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
    Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, Liu M, Tejada R, Friedrich M, Bohlen P, Witte L, Rafii S.
    Leukemia; 2003 Mar 31; 17(3):604-11. PubMed ID: 12646950
    [Abstract] [Full Text] [Related]

  • 16. ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling.
    Su M, Huang J, Li J, Qin X, Tang X, Jin F, Chen S, Jiang C, Zou Z, Peng K, Nuruzzaman M, Zhang J, Luo J, Liu S, Luo Z.
    Oncotarget; 2016 Apr 05; 7(14):19018-30. PubMed ID: 26967559
    [Abstract] [Full Text] [Related]

  • 17. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway.
    Li M, Wu S, Liu Z, Zhang W, Xu J, Wang Y, Liu J, Zhang D, Tian H, Li Y, Ye W.
    Biochem Pharmacol; 2012 May 01; 83(9):1251-60. PubMed ID: 22305746
    [Abstract] [Full Text] [Related]

  • 18. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
    Doi Y, Yashiro M, Yamada N, Amano R, Noda S, Hirakawa K.
    Ann Surg Oncol; 2012 Aug 01; 19(8):2733-43. PubMed ID: 22207048
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.